A Phase 1 Study of LY2940680 in Japanese Patients with Advanced Solid Tumors

Eli Lilly Japan K.K.0 个研究点开始时间: 2013年8月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic. The participants must be an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease
•- Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors Guideline Version 1.1
•- Have adequate organ function
•- Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy for at least 3 weeks prior to study enrollment, and have recovered from the acute effects of any such therapy
•- Males must agree to use medically approved barrier contraceptive precautions during the study and for 6 months following the last dose of study drug
•- Females with child bearing potential must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug; have had a negative serum pregnancy test equal to or less than 7 days before the first dose of study drug
•- Have an estimated life expectancy which will permit the participant to complete 2 cycles of treatment
•- Are able to swallow tablets

发起方